Cancer Clinical Trial
— IMPACTOfficial title:
Implementing Physical Activity for Individuals With Cancer During Treatment: The IMPACT Implementation-Effectiveness Trial
More Canadians are surviving cancer, however, individuals with cancer live with side effects for years after treatments have ended. The physical and psychosocial benefits of regular physical activity (PA) during and after cancer treatment are well established. However, less than 30% of individuals with cancer meet current PA recommendations and PA levels decline significantly during treatment. PA services within the cancer institution to support well-being during treatment are not available for survivors across Ontario. Strategies are needed within cancer centres to close the gap between the evidence and clinical practice. What is the purpose? To evaluate the effectiveness of a novel exercise and education strategy for individuals with cancer during treatment. What are we proposing to do? This project includes two parts. In Part 1 participants will be put into one of three groups. Group 1 (Exercise & self-management) will include eight sessions of supervised, institution-based exercise and self-management education. Group 2 (self-management only) will include eight virtual self-management education sessions with an exercise professional. Group 3 will receive usual care (i.e., no intervention). In Part 2 participants who attended less than 75% of their sessions will be asked to complete an interview on the barriers to continuing with the study during cancer treatment. Why is this work important? Findings from this trial will inform the way PA services are provided within cancer institutions across Ontario. This novel strategy incorporates both institution-based and home-based exercise strategies during treatment and highlights the importance of individuals with cancer taking an active role in managing their condition during treatment. This can prevent future complications and decrease burden on the individual and the healthcare system. Results will inform future decisions on PA implementation strategies for cancer survivors with diverse needs across Ontario.
Status | Not yet recruiting |
Enrollment | 129 |
Est. completion date | March 15, 2027 |
Est. primary completion date | March 15, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Community-dwelling - English-speaking adults - Aged over 18 years of age - Currently undergoing adjuvant or neoadjuvant chemotherapy, radiation, or hormonal therapy for cancer - Cleared by their oncologist to participate in moderate intensity aerobic exercise. Exclusion Criteria: - Self-report on the patient intake form any chronic condition, cognitive impairment, or injury that would prevent them from participating independently in moderate intensity exercise |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
McMaster University | Canadian Cancer Society (CCS), Hamilton Health Sciences Corporation, Niagara Health System |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical activity level | Godin Leisure Time Exercise Questionnaire | 16-weeks | |
Secondary | Physical activity level | Godin Leisure Time Exercise Questionnaire | 6-months | |
Secondary | Physical activity level | Godin Leisure Time Exercise Questionnaire | 12-months | |
Secondary | Quality of life | Measured using the Functional Assessment of Cancer Therapy-General (FACT-G). Total scores range from 0-108 with higher scores representing higher quality of life. | 16-weeks | |
Secondary | Quality of life | Measured using the Functional Assessment of Cancer Therapy-General (FACT-G). Total scores range from 0-108 with higher scores representing higher quality of life. | 6-months | |
Secondary | Quality of life | Measured using the Functional Assessment of Cancer Therapy-General (FACT-G). Total scores range from 0-108 with higher scores representing higher quality of life. | 12-months | |
Secondary | Level of exercise knowledge | Measured using the 'Theory of Planned Behaviour Questionnaire'. Total scores range from 8-56 with higher scores representing higher levels of exercise knowledge. | 16-weeks | |
Secondary | Level of exercise knowledge | Measured using the 'Theory of Planned Behaviour Questionnaire'. Total scores range from 8-56 with higher scores representing higher levels of exercise knowledge. | 6-months | |
Secondary | Level of exercise knowledge | Measured using the 'Theory of Planned Behaviour Questionnaire'. Total scores range from 8-56 with higher scores representing higher levels of exercise knowledge. | 12-months | |
Secondary | Health status | Measured using the Eq-5d-3L VAS. Measured on a scale of 0-100 with higher scores representing higher levels perceived health status. | 16-weeks | |
Secondary | Health status | Measured using the Eq-5d-3L VAS. Measured on a scale of 0-100 with higher scores representing higher levels perceived health status. | 6-months | |
Secondary | Health status | Measured using the Eq-5d-3L VAS. Measured on a scale of 0-100 with higher scores representing higher levels perceived health status. | 12-months | |
Secondary | Aerobic capacity | Six minute walk test | 16-weeks | |
Secondary | Aerobic capacity | Six minute walk test | 6-months | |
Secondary | Aerobic capacity | Six minute walk test | 12-months | |
Secondary | Cardiovascular outcomes - Blood pressure | Resting Blood Pressure | 16-weeks | |
Secondary | Cardiovascular outcomes - Blood pressure | Resting Blood Pressure | 6-months | |
Secondary | Cardiovascular outcomes - Blood pressure | Resting Blood Pressure | 12-months | |
Secondary | Cardiovascular outcomes - Heart rate | Resting heart rate | 16-weeks | |
Secondary | Cardiovascular outcomes - Heart rate | Resting heart rate | 6-months | |
Secondary | Cardiovascular outcomes - Heart rate | Resting heart rate | 12-months | |
Secondary | Health care utilization | Measured using the 'Health care utilization scale'. Minimum score: 0, no maximum score. Higher values represent higher health care utilization and higher costs. | 16-weeks | |
Secondary | Health care utilization | Measured using the 'Health care utilization scale'. Minimum score: 0, no maximum score. Higher values represent higher health care utilization and higher costs. | 6-months | |
Secondary | Health care utilization | Measured using the 'Health care utilization scale'. Minimum score: 0, no maximum score. Higher values represent higher health care utilization and higher costs. | 12-months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|